Thousand Oaks-based Amgen will pay a Swedish company up to $410 million to help it develop oncology and neuroscience drugs.
The companies announced the partnership Oct. 4 and said Nuevolution will use its Chemetics drug discovery platform to discover drugs for Amgen. Nuevolution may receive licensing payments along with development, commercial and milestone payments.
It will be responsible for early research while Amgen will work with the company during late-stage research. Amgen will be responsible for development, clinical development and global commercialization.
• Contact Philip Joens at [email protected]